High dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

BACKGROUND: Ursodeoxycholic acid (UDCA) in a dose of 28–30 mg/kg/day increases the likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients. AIM: Our aim was to compare the risk of adverse clinical endpoints in patients with varying disease status. METHODS: We reviewed r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Imam, Mohamad H., Sinakos, Emmanouil, Gossard, Andrea A., Kowdley, Kris V., Luketic, Velimir A. C., Harrison, M. Edwyn, McCashland, Timothy, Befeler, Alex S., Harnois, Denise, Jorgensen, Roberta, Petz, Jan, Keach, Jill, DeCook, Alisha C., Enders, Felicity, Lindor, Keith D.
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3752281/
https://ncbi.nlm.nih.gov/pubmed/21957881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2036.2011.04863.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars